Zacks: Brokerages Anticipate OncoSec Medical (ONCS) Will Post Earnings of -$0.15 Per Share

Equities analysts expect that OncoSec Medical (NASDAQ:ONCS) will report earnings per share of ($0.15) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for OncoSec Medical’s earnings, with the lowest EPS estimate coming in at ($0.21) and the highest estimate coming in at ($0.09). OncoSec Medical posted earnings of ($0.22) per share during the same quarter last year, which would indicate a positive year over year growth rate of 31.8%. The business is expected to announce its next quarterly earnings results on Thursday, June 7th.

According to Zacks, analysts expect that OncoSec Medical will report full year earnings of ($0.73) per share for the current fiscal year, with EPS estimates ranging from ($0.86) to ($0.60). For the next year, analysts forecast that the business will post earnings of ($0.56) per share, with EPS estimates ranging from ($0.71) to ($0.36). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow OncoSec Medical.

How to Become a New Pot Stock Millionaire

OncoSec Medical (NASDAQ:ONCS) last issued its quarterly earnings data on Friday, March 9th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.05).

A number of brokerages have recently issued reports on ONCS. Piper Jaffray began coverage on OncoSec Medical in a research report on Friday, February 9th. They set an “overweight” rating and a $4.00 price objective for the company. Maxim Group set a $5.00 price objective on OncoSec Medical and gave the stock a “buy” rating in a research report on Thursday, March 15th. Finally, HC Wainwright set a $6.00 price objective on OncoSec Medical and gave the stock a “buy” rating in a research report on Friday, January 19th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $5.00.

In related news, CEO Daniel J. O’connor acquired 16,667 shares of the stock in a transaction dated Monday, February 5th. The stock was bought at an average cost of $1.50 per share, for a total transaction of $25,000.50. Following the completion of the transaction, the chief executive officer now directly owns 16,667 shares of the company’s stock, valued at $25,000.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 5.50% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. MYDA Advisors LLC acquired a new stake in OncoSec Medical during the fourth quarter worth approximately $145,000. J. Goldman & Co LP acquired a new stake in OncoSec Medical during the fourth quarter worth approximately $163,000. Deutsche Bank AG acquired a new stake in OncoSec Medical during the fourth quarter worth approximately $261,000. Finally, Renaissance Technologies LLC acquired a new stake in OncoSec Medical during the fourth quarter worth approximately $272,000. 8.72% of the stock is owned by institutional investors and hedge funds.

Shares of ONCS opened at $1.77 on Monday. OncoSec Medical has a 1 year low of $0.88 and a 1 year high of $2.95.

COPYRIGHT VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another site, it was stolen and reposted in violation of US & international copyright & trademark law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/12/zacks-brokerages-anticipate-oncosec-medical-oncs-will-post-earnings-of-0-15-per-share.html.

About OncoSec Medical

OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer.

Get a free copy of the Zacks research report on OncoSec Medical (ONCS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply